Cargando…

Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes

Atherosclerotic cardiovascular disease remains a major cause of death and disability, especially for high-risk familial hypercholesterolemia individuals. PCSK9i (proprotein convertase subtilisin kexin type 9 inhibitors) reduce low-density lipoprotein cholesterol levels and cardiovascular event rates...

Descripción completa

Detalles Bibliográficos
Autores principales:	Myers, Kelly D., Farboodi, Niloofar, Mwamburi, Mkaya, Howard, William, Staszak, David, Gidding, Samuel, Baum, Seth J., Wilemon, Katherine, Rader, Daniel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665275/ https://www.ncbi.nlm.nih.gov/pubmed/31331194 http://dx.doi.org/10.1161/CIRCOUTCOMES.118.005404

Ejemplares similares

PCSK9 inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payers
por: Baum, Seth J., et al.
Publicado: (2017)

COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD
por: Myers, Kelly D., et al.
Publicado: (2021)

Letter to the Editor in response to “Response to Kovanen PT, et al. Letter to the Editor” for original article COVID-19 increases risk of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD
por: Myers, Kelly D., et al.
Publicado: (2021)

Different associations of premorbid intelligence vs. current cognition with BMI, insulin and diabetes in the homebound elderly
por: Mwamburi, Mkaya, et al.
Publicado: (2016)

PCSK9 inhibitor valuation: A science‐based review of the two recent models
por: Baum, Seth J., et al.
Publicado: (2018)

PCSK9 inhibitors in the prevention of cardiovascular disease
por: Latimer, James, et al.
Publicado: (2016)

PCSK9 as a therapeutic target for cardiovascular disease
por: Zhang, Pei-Ying
Publicado: (2017)

Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
por: Glerup, Simon, et al.
Publicado: (2017)

Yield of Familial Hypercholesterolemia Genetic and Phenotypic Diagnoses After Electronic Health Record and Genomic Data Screening
por: Gidding, Samuel S., et al.
Publicado: (2023)

PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort
por: Small, Aeron M., et al.
Publicado: (2020)

Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis
por: Kongnakorn, Thitima, et al.
Publicado: (2014)

Residential Traffic Exposure, Pulse Pressure, and C-reactive Protein: Consistency and Contrast among Exposure Characterization Methods
por: Rioux, Christine L., et al.
Publicado: (2010)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
por: Sobati, Saeideh, et al.
Publicado: (2020)

PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
por: Sundararaman, Sai Sahana, et al.
Publicado: (2021)

PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
por: Jia, Xiaoming, et al.
Publicado: (2022)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics
por: Khoshnejad, Makan, et al.
Publicado: (2019)

Association between Amylin and Amyloid-β Peptides in Plasma in the Context of Apolipoprotein E4 Allele
por: Qiu, Wei Qiao, et al.
Publicado: (2014)

Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion
por: Bradshaw, Steven E., et al.
Publicado: (2016)

Gene Therapy Targeting PCSK9
por: Katzmann, Julius L., et al.
Publicado: (2022)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats
por: Zhang, Yan, et al.
Publicado: (2014)

PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era
por: Chapman, M. John, et al.
Publicado: (2015)

Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk
por: Behr, Paulo Eduardo Ballvé, et al.
Publicado: (2018)

Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors
por: Pećin, Ivan, et al.
Publicado: (2017)

Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
por: Hwang, Hyeon Seok, et al.
Publicado: (2020)

PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis
por: Bodapati, Adi prasad, et al.
Publicado: (2023)

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
por: Konrad, Robert J, et al.
Publicado: (2011)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Genetic analysis of the PCSK9 locus in psychological, psychiatric, metabolic and cardiovascular traits in UK Biobank
por: Hay, Rachel, et al.
Publicado: (2022)

PCSK9 inhibition in high-risk patients
por: Zijlstra, Laurien E., et al.
Publicado: (2019)

Plasma Amylin and Cognition in Diabetes in the Absence and the Presence of Insulin Treatment
por: Qiu, Wei Qiao, et al.
Publicado: (2014)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020)

Autocrine effects of PCSK9 on cardiomyocytes
por: Wolf, Annemarie, et al.
Publicado: (2020)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pt813esjc26qa71pc4tt6enuc2